ArticleJACC. Case reports2025
Fulminant Myocarditis After mRNA COVID-19 Vaccine Evolving to Giant Cell Myocarditis.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPediatric inflammatory multisystem syndrome (PIMS-TS) is a rare entity observed in children with postinfectious hyperinflammatory syndrome. Cases have been reported, although rarely, after the mRNA SARS-CoV-2 (COVID-19) vaccine. CASE SUMMARY: We present a case of a young man who developed PIMS-TS with fulminant myocarditis after a first dose of COVID-19 vaccination, with persistent evidence of inflammation despite multiple lines of therapy over the course of 2 years. He then experienced fulminant myocarditis that was resistant to anti-inflammatory therapies. Repeat endomyocardial biopsy was consistent with giant cell myocarditis. DISCUSSION: Cases of giant cell myocarditis after COVID-19 vaccination have been reported in the past, however to our knowledge, none have been reported 2 years after a single dose and with intercurrent diagnosis of PIMS-TS myocarditis. This raises the question of a possible pathophysiologic association between the 2 diseases and immune dysregulation. TAKE-HOME MESSAGE: This case illustrates the importance of repeating the investigation and questioning the diagnosis when the progression of the disease is not typical.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.